Intensification versus combination: revisiting the past and envisioning the future of LDHA inhibitors
Cancer Chemotherapy and Pharmacology · 20.08.2026 · 96 (1)
DOI: 10.1007/s00280-026-04918-5 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancer Chemotherapy and Pharmacology, online erschienen am 20.08.2026. Verfasst von Weixi Yuan und 12 weiteren Autor:innen. Beteiligte Einrichtung: The First Affiliated Hospital, Department of Pharmacy, Institute of Pharmacy and Pharmacology, Hengyang Medical School, University of South China, He…. Hauptthemen laut MEDLINE: Neoplasms, Enzyme Inhibitors, Lactate Dehydrogenase 5, Antineoplastic Agents. Die Arbeit nennt 116 Literaturangaben. Gefördert von: Hunan Provincial Key Laboratory of Tumor Microenvironment responsive Drug Research, National Natural Science Foundation of China, Natural Science Foundation of Hunan Province.
Abstract (Originalsprache)
As a key enzyme in pyruvate metabolism, lactate dehydrogenase A (LDHA) has been extensively studied for its role in cellular energy regulation and disease pathology. Given its central role in the Warburg effect (cancer cells have a higher intensity of glycolysis even under oxygen-rich conditions) cytoplasmic LDHA emerges as a strategic therapeutic target for tumor suppression through glycolytic pathway inhibition. Despite extensive research, the development of effective LDHA inhibitors has seen limited success, highlighting the urgent need to reassess its molecular properties and refine drug design strategies. In this review, we systematically analyze LDHA's structural biology, critically evaluate the strengths and shortcomings of current inhibitors, and propose novel conceptual frameworks for inhibitor development based on recent insights into LDHA-mediated glycolysis reprogramming. By integrating recent insights into LDHA-mediated glycolysis reprogramming, this review lays the groundwork for rational inhibitor design and its clinical application, either as monotherapy or in combination treatments for cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The First Affiliated Hospital, Department of Pharmacy, Institute of Pharmacy and Pharmacology, Hengyang Medical School, University of South China, Hengyang, 421001, Hunan, China.
- Pharmacy Department, The First People's Hospital of Xiangtan City, Xiangtan Hospital Affiliated to University of South China, Xiangtan, 411101, Hunan, PR China.
- The Second Affiliated Hospital, Department of Pharmacy, Hengyang Medical School, University of South China, Hengyang, 421001, Hunan, China.
- Hunan Haopifu Pharmaceutical Co., Ltd, Hunan, China.
- Department of Pharmacy, Xiangnan University, Chenzhou, 423000, China.
- The First Affiliated Hospital, Department of Pharmacy, Institute of Pharmacy and Pharmacology, Hengyang Medical School, University of South China, Hengyang, 421001, Hunan, China. ybnhfy@126.com.
Förderung
- Hunan Provincial Key Laboratory of Tumor Microenvironment responsive Drug Research
- National Natural Science Foundation of China
- Natural Science Foundation of Hunan Province
Zitieren
APA
Yuan, W., Kang, Q., Zhao, Y., Wang, Z., He, Y., Fu, C., Xiao, H., Lei, X., Xie, Z., Yang, X., Yang, B., Tang, G., & Deng, X. (2026). Intensification versus combination: revisiting the past and envisioning the future of LDHA inhibitors. Cancer Chemotherapy and Pharmacology, 96(1). https://doi.org/10.1007/s00280-026-04918-5
Vancouver
Yuan W, Kang Q, Zhao Y, Wang Z, He Y, Fu C, et al. Intensification versus combination: revisiting the past and envisioning the future of LDHA inhibitors. Cancer Chemotherapy and Pharmacology. 2026;96(1). doi:10.1007/s00280-026-04918-5
BibTeX
@article{Yuan2026,
author = {Yuan, Weixi and Kang, Qiang and Zhao, Yin and Wang, Zhe and He, Yujia and Fu, Chengxiao and Xiao, Hongxiang and Lei, Xiaoyong and Xie, Zhizhong and Yang, Xiaoyan and Yang, Bo and Tang, Guotao and Deng, Xiangping},
title = {Intensification versus combination: revisiting the past and envisioning the future of LDHA inhibitors},
journal = {Cancer Chemotherapy and Pharmacology},
year = {2026},
volume = {96},
number = {1},
doi = {10.1007/s00280-026-04918-5}
}
EUVIMED